Dec 23, 2024 · Most significant clinical trials of 2024. From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.

Oct 21, 2024 · At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections. As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden.

Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to meet its primary efficacy goals.. The vaccine aimed to reduce lesions in patients with recurrent genital herpes – a high unmet medical need. Although deemed safe, its lack of efficacy led to GSK’s decision not to ...

Nov 14, 2024 · Paratek Pharmaceuticals has announced positive top-line safety, efficacy, and tolerability data from a Phase IIb study of oral omadacycline. In a study of 66 adult patients with nontuberculous mycobacteria pulmonary disease (NTM-PD) caused by mycobacterium abscessus complex (MABc), oral omadacycline was found to be generally safe and well-tolerated, in addition to demonstrating higher response ...

Sep 13, 2024 · The vaccine was safe and well tolerated in the first cohort, with adverse events (AEs) including fatigue, injection site pain and fever. Researchers are asking for the interim data to be treated with caution at this early stage due to the small sample size and primary endpoint being safety and dose-determining.

Oct 8, 2024 · Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience and cost-effectiveness.

Jul 2, 2024 · Insurers and government programmes may be reluctant to cover costly treatments. In August 2017, Kymriah broke ground by becoming the first CAR T-cell therapy in the world to gain approval to treat acute lymphoblastic leukaemia in the US, followed closely by Yescarta.

Dec 18, 2023 · The year 2023 started with disappointing news for the field of human immunodeficiency virus (HIV) research after Janssen’s Phase III vaccine trial failed.. This setback has had a major impact on the industry and emphasised the need for better treatment and prevention against the virus while researchers continue to push for a vaccine.

Jan 17, 2024 · Aruna Bio co-founder and chief scientific officer Steven Stice said: “We are thrilled with this validation from the FDA, which not only positions AB126 as the first exosome to enter human clinical trials for a neurological indication, but …

JP Morgan 2025: Jazz Pharmaceuticals focusing on oncology pipeline. Jazz Pharmaceuticals plans to expand indications for two oncology drugs, namely zanidatamab and Zepzelca.